Search Results - "Velders, M P"

Refine Results
  1. 1

    Role of alkaline phosphatase in colitis in man and rats by Tuin, A, Poelstra, K, de Jager-Krikken, A, Bok, L, Raaben, W, Velders, M P, Dijkstra, G

    Published in Gut (01-03-2009)
    “…Crohn's disease (CD) and ulcerative colitis (UC) are chronic multifactorial inflammatory bowel diseases (IBDs) with unknown aetiology, but a deregulated…”
    Get more information
    Journal Article
  2. 2

    Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells by Gabrilovich, Dmitry I, Velders, Markwin P, Sotomayor, Eduardo M, Kast, W. Martin

    Published in The Journal of immunology (1950) (01-05-2001)
    “…The mechanism of tumor-associated T cell dysfunction remains an unresolved problem of tumor immunology. Development of T cell defects in tumor-bearing hosts…”
    Get full text
    Journal Article
  3. 3

    Ep-CAM: A Human Epithelial Antigen Is a Homophilic Cell-Cell Adhesion Molecule by Litvinov, Sergey V., Velders, Markwin P., Hellen A. M. Bakker, Fleuren, Gert Jan, Warnaar, Sven O.

    Published in The Journal of cell biology (01-04-1994)
    “…The epithelial glycoprotein 40 (EGP40, also known as GA733-2, ESA, KSA, and the 17-1A antigen), encoded by the GA-733-2 gene, is expressed on the baso-lateral…”
    Get full text
    Journal Article
  4. 4
  5. 5

    The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas by VELDERS, M. P, VAN RHIJN, C. M, OSKAM, E, FLEUREN, G. J, WARNAAR, S. O, LITVINOV, S. V

    Published in British journal of cancer (01-08-1998)
    “…Antibody-dependent cellular cytotoxicity (ADCC) is considered to be the major mechanism through which tumour cells, upon treatment with anti-tumour MAbs, are…”
    Get full text
    Journal Article
  6. 6

    Modulation of the immune response and tumor growth by activated Ras by WEIJZEN, S, VELDERS, M. P, KAST, W. M

    Published in Leukemia (01-04-1999)
    “…As a result of its transforming abilities, activated Ras is expressed in a great number of cancers. The ras mutation frequency varies between 95% in pancreatic…”
    Get full text
    Journal Article
  7. 7

    Prospects for immunotherapy of acute lymphoblastic leukemia by VELDERS, M. P, TER HORST, S. A. J, KAST, W. M

    Published in Leukemia (01-05-2001)
    “…Acute lymphoblastic leukemia (ALL) is diagnosed in approximately 100000 people worldwide per year and 70% of the patients are children. Most children have a…”
    Get full text
    Journal Article
  8. 8

    Active immunization against cancer cells: impediments and advances by Velders, M P, Schreiber, H, Kast, W M

    Published in Seminars in oncology (01-12-1998)
    “…Immunotherapy of cancer is still mainly an experimental treatment. Some monoclonal antibodies have been approved for adjuvant therapy of cancer in patients,…”
    Get more information
    Journal Article
  9. 9

    Pharmacokinetic Differences Between a T Cell-Tolerizing and a T Cell-Activating Peptide by Weijzen, Sanne, Meredith, Stephen C, Velders, Markwin P, Elmishad, Amira G, Schreiber, Hans, Kast, W. Martin

    Published in The Journal of immunology (1950) (15-06-2001)
    “…Vaccination with a peptide representing a CTL epitope from the human papillomavirus (HPV)16 E7 protein induces a specific CTL response that prevents the…”
    Get full text
    Journal Article
  10. 10

    Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles by Rudolf, M P, Nieland, J D, DaSilva, D M, Velders, M P, Müller, M, Greenstone, H L, Schiller, J T, Kast, W M

    Published in Biological chemistry (01-03-1999)
    “…It has been postulated that upon binding to a cell surface receptor, papilloma virus-like particles (VLPs) gain entry into the cytosol of infected cells and…”
    Get more information
    Journal Article
  11. 11

    New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency by VELDERS, M. P, LITVINOV, S. V, WARNAAR, S. O, GORTER, A, FLEUREN, G. J, ZURAWSKI, V. R, CONEY, L. R

    Published in Cancer research (Chicago, Ill.) (01-04-1994)
    “…The monoclonal antibodies (MAbs) 323/A3 and 17-1A both recognize a 40-kDa carcinoma-associated epithelial glycoprotein (EGP40). MAb 17-1A has been used in many…”
    Get full text
    Journal Article
  12. 12

    Eradication of established tumors by vaccination with venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA by VELDERS, Markwin P, MCELHINEY, Sue, CASSETTI, Maria Cristina, EIBEN, Gretchen L, HIGGINS, Terry, KOVACS, Gerald R, ELMISHAD, Amira G, KAST, W. Martin, SMITH, Larry R

    Published in Cancer research (Chicago, Ill.) (01-11-2001)
    “…The etiological role of human papillomaviruses (HPV) in cervical and other cancers suggests that therapeutic vaccines directed against requisite viral antigens…”
    Get full text
    Journal Article
  13. 13

    The Notch Ligand Jagged-1 Is Able to Induce Maturation of Monocyte-Derived Human Dendritic Cells by Weijzen, Sanne, Velders, Markwin P, Elmishad, Amira G, Bacon, Patricia E, Panella, Jeffrey R, Nickoloff, Brian J, Miele, Lucio, Kast, W. Martin

    Published in The Journal of immunology (1950) (15-10-2002)
    “…Notch receptors play a key role in several cellular processes including differentiation, proliferation, and apoptosis. This study investigated whether the…”
    Get full text
    Journal Article
  14. 14

    Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude mouse xenograft carcinoma model by VELDERS, M. P, VAN RHIJN, C. M, BRIAIRE, I. H, FLEUREN, G. J, WARNAAR, S. O, LITVINOV, S. V

    Published in Cancer research (Chicago, Ill.) (01-10-1995)
    “…The therapeutic effects of the low and high affinity mAbs 17-1A and 323/A3 were investigated in nude mice xenografted with LS 180 human colorectal carcinoma…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Establishment of an HLA-A0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A0201 transgenic mice by EIBEN, Gretchen L, VELDERS, Markwin P, SCHREIBER, Hans, CASSETTI, Maria Cristina, PULLEN, Jeffrey K, SMITH, Larry R, KAST, W. Martin

    Published in Cancer research (Chicago, Ill.) (15-10-2002)
    “…With the increasing generation of new cancer vaccine strategies, there is also an increasing demand for preclinical models that can carefully predict the…”
    Get full text
    Journal Article
  17. 17

    The role of monoclonal antibody affinity in tumor immunotherapy evaluated in in vivo models for minimal residual disease by Velders, M P, van Rhijn, C M, Cornelissen, I M, van Muijen, G N, Briaire, I H, Dohlsten, M, Fleuren, G J, Warnaar, S O, Litvinov, S V

    “…To evaluate the role of affinity in monoclonal antibody (mAb)-mediated treatment of carcinomas, we compared the antibodies 17-1A and 323/A3 that bind with…”
    Get more information
    Journal Article
  18. 18

    Physical interaction of human papillomavirus virus-like particles with immune cells by Da Silva, Diane M., Velders, Markwin P., Nieland, John D., Schiller, John T., Nickoloff, Brian J., Kast, W. Martin

    Published in International immunology (01-05-2001)
    “…Human papillomavirus virus-like particles (HPV VLP) and chimeric VLP are immunogens that are able to elicit potent anti-viral/tumor B and T cell responses. To…”
    Get full text
    Journal Article
  19. 19

    Human T cell responses to endogenously presented HLA-A0201 restricted peptides of simian virus 40 large T antigen by Velders, Markwin P., Macedo, M. Fatima, Provenzano, Maurizio, Elmishad, Amira G., Holzhütter, Hermann-Georg, Carbone, Michele, Kast, W. Martin

    Published in Journal of cellular biochemistry (01-07-2001)
    “…Presence of the simian virus 40 (SV40) has recently been demonstrated in a relatively high percentage of human mesotheliomas and it is associated with the…”
    Get full text
    Journal Article
  20. 20

    A Murine Model for the Effects of Pelvic Radiation and Cisplatin Chemotherapy on Human Papillomavirus Vaccine Efficacy by SMALL, Laurie A, DA SILVA, Diane M, DE VISSER, Karin E, VELDERS, Markwin P, FISHER, Susan G, POTKUL, Ronald K, KAST, W. Martin

    Published in Clinical cancer research (01-03-2001)
    “…Therapeutic human papillomavirus (HPV) vaccines for cervical cancer depend on a competent immune system to be effective. However, cancer patients are often…”
    Get full text
    Journal Article Conference Proceeding